Glasgow Health And Rehabilitation Center | |
120 Melrose Drive, Box 350, Glasgow, West Virginia 25086 | |
(304) 595-1155 | |
Name | Glasgow Health And Rehabilitation Center |
---|---|
Location | 120 Melrose Drive, Box 350, Glasgow, West Virginia |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 112 |
Occupancy Rate | 56.43% |
Medicare ID (CCN) | 515118 |
Legal Business Name | Glasgow Operating Company Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1336890789 |
Organization Name | GLASGOW HEALTH AND REHABILITATION |
Address | 120 Melrose Dr, Glasgow, WV 25086 |
Phone Number | 304-595-1155 |
News Archive
New research shows that a novel positron emission tomography (PET) tracer that targets inflammation is safe and can clearly identify early stages of rheumatoid arthritis.
Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.
To address the skyrocketing costs of out-of–pocket medical expenses, Health In Reach, Inc. today announced a new Internet-based service to make health care more accessible and affordable.
Heavy snowfall slows things down and makes it harder to get from point A to point B. But snow clouds have a silver lining-heavy snow may prevent serious road injuries and even save lives. How? By getting people off bicycles and switching to safer modes of transport.
› Verified 3 days ago
NPI Number | 1487192753 |
Organization Name | GLASGOW OPERATING COMPANY LLC |
Doing Business As | GLASGOW HEALTH AND REHABILITION CENTER |
Address | 120 Melrose Drive, Glasgow, WV 25086 |
Phone Number | 304-595-1155 |
News Archive
New research shows that a novel positron emission tomography (PET) tracer that targets inflammation is safe and can clearly identify early stages of rheumatoid arthritis.
Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.
To address the skyrocketing costs of out-of–pocket medical expenses, Health In Reach, Inc. today announced a new Internet-based service to make health care more accessible and affordable.
Heavy snowfall slows things down and makes it harder to get from point A to point B. But snow clouds have a silver lining-heavy snow may prevent serious road injuries and even save lives. How? By getting people off bicycles and switching to safer modes of transport.
› Verified 3 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
New research shows that a novel positron emission tomography (PET) tracer that targets inflammation is safe and can clearly identify early stages of rheumatoid arthritis.
Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.
To address the skyrocketing costs of out-of–pocket medical expenses, Health In Reach, Inc. today announced a new Internet-based service to make health care more accessible and affordable.
Heavy snowfall slows things down and makes it harder to get from point A to point B. But snow clouds have a silver lining-heavy snow may prevent serious road injuries and even save lives. How? By getting people off bicycles and switching to safer modes of transport.
› Verified 3 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 22.32 | 14.46 |
Percentage of long-stay residents who lose too much weight | 13.16 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 40.82 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.44 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 1.23 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 8.03 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.27 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 6.03 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 60.13 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 2.56 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 18.31 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 24.03 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 10.06 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.55 | 95.98 |
Percentage of short-stay residents who made improvements in function | 81.15 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 74.42 | 82.93 |
News Archive
New research shows that a novel positron emission tomography (PET) tracer that targets inflammation is safe and can clearly identify early stages of rheumatoid arthritis.
Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.
To address the skyrocketing costs of out-of–pocket medical expenses, Health In Reach, Inc. today announced a new Internet-based service to make health care more accessible and affordable.
Heavy snowfall slows things down and makes it harder to get from point A to point B. But snow clouds have a silver lining-heavy snow may prevent serious road injuries and even save lives. How? By getting people off bicycles and switching to safer modes of transport.
› Verified 3 days ago
Glasgow Health And Rehabilitation Center Location: 120 Melrose Drive, Box 350, Glasgow, West Virginia 25086 Phone: (304) 595-1155 |